Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor,
Pfizer reports positive data from prostate cancer combination therapy trial
Pfizer has announced data from the Phase III trial of TALZENNA plus XTANDI in patients with metastatic castration-resistant prostate cancer.
Pfizer Reports Positive Topline Data From Phase 3 TALAPRO-2 Study Of Talzenna Plus Xtandi
Thursday reported positive topline results from the Phase 3 TALAPRO-2 study of Talzenna in combination with Xtandi
Pfizer announces positive data from late-stage trial of prostate cancer combo treatment
Pfizer Inc. announced positive results Thursday from the final analysis of data from a late-stage trial of a combination treatment for patients with metastatic castration-resistant prostate cancer, or mCRPC.
FiercePharma
6d
Pfizer targets broad Talzenna approval in prostate cancer as trial meets patient survival goal
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
Cure Today
1d
Why ‘Genetic Testing is Critical’ in Patients with Prostate Cancer
As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in ...
The Pharma Letter
6d
Pfizer’s Talzenna and Xtandi combo prolongs OS in mCRPC
US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...
7d
Pfizer's cancer drug combo improves overall survival in late-stage study
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
BioSpace
6d
Pfizer Phase III Prostate Cancer Win Builds Case for Broader Label for Talzenna-Xtandi Combo
The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Pfizer
Xtandi
Enzalutamide
Ordnance Survey
Feedback